期刊文献+

食管鳞癌组织中p53和HER-2表达及其临床意义 被引量:1

Expression and clinical significance of p53 and HER-2 in esophageal squamous cell carcinoma
下载PDF
导出
摘要 目的:探讨食管鳞癌组织(ESCC)中p53和HER-2的表达及其与临床病理及生存时间之间的相关性。方法:免疫组织化学法检测102例已行手术切除的食管鳞癌组织中p53和HER-2的表达水平,分析比较p53及HER-2两者的相关性,及两者和临床病理之间的关系,比较p53和HER-2的表达水平和患者平均生存时间之间的相关性。结果:102例ESCC组织中56例癌组织的p53表达阳性(54.90%)。其阳性表达与患者性别、年龄、病变长度、部位、临床TNM分期、癌细胞分化程度、区域淋巴结转移未呈现相关性(P>0.05);22例患者癌组织HER-2表达阳性(21.57%),其阳性与组织分化程度、区域淋巴结转移正相关(P<0.05);与患者的年龄、性别、病变部位、病变长度及临床TNM分期未见有相关性(P>0.05)。HER-2与p53两者的表达显著正相关(r=0.343,P=0.01)。通过随访,HER-2表达阳性组生存时间与阴性组比较有显著差异,前者生存时间较后者短(37.37±1.75个月vs 44.71±1.37个月,P<0.05);p53表达阳性组与阴性组未见显著性差异(40.37±0.76个月vs 44.11±1.15个月,P>0.05)。结论:p53与HER-2蛋白在ESCC中均过表达,HER-2蛋白过表达可能提示预后不良,p53过表达与预后无相关性,两者可能在ESCC的发生、发展中存在相关性。 Objective : To study the expression of p53 and HER - 2 oncogene in esophageal squamous cell carcino- ma(ESCC) ,and explore the relation between the clinical and pathological characteristics and survival time. Methods:By immunohistochemical method, we detected p53 and HER- 2 oncogene expression in 102 cases of ESCC tissue after surgical resection, and investigated the correlation between p53 and HER -2, and the clinicopathologie characteristics. Results:p53 expressed positively(54.90% ) in ESCC tissue, and there was no correlation in ESCC differentiation degree, gender, age, disease length,location and TNM stage, tissue cell differentiation degree,lymph node metastasis (P 〉 0.05). The expression of HER -2 was 21.57%. Patients with ESCC with positive expression had shorter survival time than those with negative expression on HER - 2 (37.37 ±1.75months vs 44.71 ±1.37months,P 〈 0.05 ) , while the expression of p53 did not differed ( 40.37 ±0.76months vs 44. 11 ±1.15months,P 〉 0. (15). Conclusion:p53 and HER -2 overexpressed in ESCC, p53 plays an important role in the development of ESCC. Cases with positive HER - 2 expression have shorter survival time than those with negative HER - 2 expression, p53 positive and negative groups did not see significant difference. The expression of p53 and HER- 2 gene has close correlation.
出处 《现代肿瘤医学》 CAS 2014年第1期98-101,共4页 Journal of Modern Oncology
关键词 HER-2 P53 食管肿瘤 预后 HER - 2 p53 esophageal tumor prognosis
  • 相关文献

参考文献11

  • 1陈灏珠;林果为.内科学[M]{H}北京:人民卫生出版社,20091958-1962.
  • 2Ma J,Zhang J,Ning T. Association of genetic polymorphisms in MDM2,PTEN and p53 with risk of esophageal squamous cell carcinoma[J].{H}Journal of Human Genetics,2012.16.
  • 3胡文静,刘宝瑞,钱晓萍,杨阳,邹征云,王立峰.COX-2和HER-2在非小细胞肺癌中的表达及临床意义[J].实用临床医药杂志,2009,13(7):35-38. 被引量:6
  • 4Eqashira A,Morita M,Yoshida R. Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival:analyses of gene mutations,protein expression,and loss of heterozygosity in Japanese patients[J].{H}Journal of Surgical Oncology,2011,(02):169-175.
  • 5Wang LS,Chow KC,Chi KH. Prognosis of esophageal squamous cell carcinoma:analysis of clinicopathological and biological factors[J].{H}American Journal of Gastroenterology,1999,(07):1933-1940.
  • 6赵坤,黄俊星.EGFR、Her-2在食管鳞癌中表达的研究进展[J].现代肿瘤医学,2011,19(8):1688-1690. 被引量:4
  • 7Mimura K,Kono K,Hanawa M. Frequencies of HER-2neu expression and gene amplification in patients with oesophageal squamous cell carcinoma[J].{H}British Journal of Cancer,2005,(07):1253-1260.
  • 8邓勇军,李海滨,沈剑,杨鸿生,洪志鹏,李定彪.食管鳞癌中人表皮生长因子受体Her-2/neu蛋白的过表达及预后意义[J].中国现代医学杂志,2009,19(24):3726-3730. 被引量:10
  • 9K Mimura,M Hanawa,F Mitsui. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma[J].{H}British Journal of Cancer,2005,(10):1253-1260.
  • 10Bang YJ,Van Custem E,Feyerislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2 positive advanced gastric or gastrooesophgeal junction cacer(ToGA):a phase 3,open-label,randomized control trial[J].{H}LANCET,2010,(9742):687-697.

二级参考文献48

  • 1葛棣,冯明祥,曾亮.表皮生长因子受体家族在食管癌中表达的临床研究[J].中国临床医学,2004,11(5):717-720. 被引量:11
  • 2刘昭前,李慧华,周宏灏.吉非替尼治疗非小细胞肺癌的研究进展[J].中国现代医学杂志,2005,15(20):3133-3136. 被引量:5
  • 3Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer [J]. Am J Ther, 2005, 12(3): 243-253.
  • 4AGUS DB, BUNN PA JR, FRANKLIN W, et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer[J]. Semin Oncol, 2000, 27(6 Suppl 11): 53-63.
  • 5GREENE FL, COMP TON CC, FRITZ A G, et al. MCC Cancer Staging. Atlas[M]. New York: Springer, 2006: 77-88.
  • 6WOLFF AC, HAMMOND ME, SCHWARTZ JN, et al. American society of clinical oneology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. J Clin Oncol, 2007, 25(1): 118-145.
  • 7LAUDADIO J, QUIGLEY DI, TUBBS R, et al. HER2 testing: a review of detection methodologies and their clinical performance [J]. Expert Rev Mol Diagn, 2007, 7(1): 53-64.
  • 8DREILICH M, WANDERS A, BRATPSTROM D, et al. HER-2 overexpression (3+) in patients with squamous ceU esophageal carcinoma correlates with poorer survival[J]. Dis Esophagus, 2006, 19(4): 224-231.
  • 9AKAMATSU M, MATSUMOTO T, OKA K. C-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(5): 1323-1327.
  • 10SATO S, KAJIYAMA Y, SUGANO M. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein [J]. Int J Radiat Oncol Biol Phys, 2005, 61(1): 203-211.

共引文献17

同被引文献30

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部